Infectious disease
Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
As usual, there was plenty of clinical trial news last week. Here’s a look.
Merck is joining the ranks of pharmaceutical companies that have a COVID-19 vaccine candidate in clinical development. Merck will move its candidate into clinical trials in the third quarter of this year, the company announced this morning.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.
As Moderna launched its Phase III clinical trial of its COVID-19 vaccine this week, a member of the company’s board of directors, Elizabeth “Betsy” Nabel, resigned to avoid any conflict of interest.
The vaccine was developed by Preston Estep, a former graduate student of Harvard University geneticist George Church.
This morning Johnson & Johnson announced preclinical data that showed its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19.
The U.S. FDA issued a new template for clinical test developers that is designed to assist these companies in developing and submitting emergency use authorization (EUA) for COVID-19 tests that can be performed at home or in other settings besides laboratories.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
PRESS RELEASES